Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels

Benzinga

2026.10.26 07:12 (GMT+0)

Abrir em Benzinga